Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding

Crystal structure of human serum albumin at 2.5 Å resolution

Sugio, S., Kashima, A., Mochizuki, S., Noda, M., & Kobayashi, K. (1999) · Protein Engineering Design and Selection · doi:10.1093/protein/12.6.439 · Cited by 1,790 · see citing works

Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites

Curry, S., Mandelkow, H., Brick, P., & Franks, N. P. (1998) · Nature Structural Biology · doi:10.1038/1869 · Cited by 1,378 · see citing works

Quantitative analysis of protein far UV circular dichroism spectra by neural networks

Böhm, G., Muhr, R., & Jaenicke, R. (1992) · Protein Engineering Design and Selection · doi:10.1093/protein/5.3.191 · Cited by 1,107 · see citing works

Therapeutic antibodies for autoimmunity and inflammation

Chan, A. C., & Carter, P. J. (2010) · Nature reviews. Immunology · doi:10.1038/nri2761 · Cited by 835 · see citing works

Impact of albumin on drug delivery — New applications on the horizon

Elsadek, B., & Kratz, F. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 834 · see citing works

Enhanced antibody half-life improves in vivo activity

Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 657 · see citing works

The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · see citing works

Crystal structural analysis of human serum albumin complexed with hemin and fatty acid

Zunszain, P. A., Ghuman, J., Komatsu, T., Tsuchida, E., & Curry, S. (2003) · BMC Structural Biology · doi:10.1186/1472-6807-3-6 · Cited by 509 · see citing works

Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies

Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502 · see citing works

Albumin as a versatile platform for drug half-life extension

Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 490 · see citing works

Crystal structure of the complex of rat neonatal Fc receptor with Fc

Burmeister, W. P., Huber, A. H., & Björkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 432 · see citing works

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · see citing works

Crystal structure of the complex of rat neonatal Fc receptor with Fc

(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 382 · see citing works

A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus.

Story, C. M., Mikulska, J., & Simister, N. E. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2377 · Cited by 346 · see citing works

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease

Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Khabbaz, H. J. A., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 315 · see citing works

Albumin Binding to FcRn: Distinct from the FcRn−IgG Interaction

Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290 · see citing works

Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates

Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 274 · see citing works

Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism

Akilesh, S., Christianson, G. J., Roopenian, D. C., & Shaw, A. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4580 · Cited by 269 · see citing works

Crystallographic Analysis of Human Serum Albumin Complexed with 4Z,15E-Bilirubin-IXα

Zunszain, P. A., Ghuman, J., McDonagh, A. F., & Curry, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.016 · Cited by 267 · see citing works

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · see citing works

Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor ,

West, A. P., & Björkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 256 · see citing works

Increasing the serum persistence of an IgG fragment by random mutagenesis

Ghetie, V. F., Popov, S. G., Borvak, J., Radu, C. G., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 242 · see citing works

Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice

Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., & Ward, E. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810796106 · Cited by 211 · see citing works

Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding

Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E., & Sandlie, I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081828 · Cited by 199 · see citing works

Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor

Andersen, J. T., Dalhus, B., Cameron, J., Daba, M. B., Plumridge, A., Evans, L. R., Brennan, S. O., Gunnarsen, K. S., Bjørås, M., Sleep, D., et al. (2012) · Nature Communications · doi:10.1038/ncomms1607 · Cited by 199 · see citing works

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Santagostino, E., Négrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I. C., & Morfini, M. (2012) · Blood · doi:10.1182/blood-2012-05-429688 · Cited by 177 · see citing works

The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics

Andersen, J. T., & Sandlie, I. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.318 · Cited by 123 · see citing works

The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH‐dependent binding to albumin

Andersen, J. T., Qian, J. D., & Sandlie, I. (2006) · European Journal of Immunology · doi:10.1002/eji.200636556 · Cited by 118 · see citing works

Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface

Schmidt, M. M., Townson, S. A., Andreucci, A., King, B. M., Schirmer, E. B., Murillo, A., Dombrowski, C., Tisdale, A. W., Lowden, P., Masci, A., et al. (2013) · Structure · doi:10.1016/j.str.2013.08.022 · Cited by 116 · see citing works

An FcRn-Dependent Role for Anti-flagellin Immunoglobulin G in Pathogenesis of Colitis in Mice

Kobayashi, K., Qiao, S., Yoshida, M., Baker, K., Lencer, W. I., & Blumberg, R. S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.059 · Cited by 86 · see citing works

Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner

Andersen, J. T., Cameron, J., Plumridge, A., Evans, L. R., Sleep, D., & Sandlie, I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463000 · Cited by 67 · see citing works

Cloning and Expression of the Neonatal Rat Intestinal Fc Receptor, a Major Histocompatibility Complex Class I Antigen HomologPreprint

Simister, N. E., & Mostov, K. E. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.068 · Cited by 64 · see citing works

The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae

Evans, L. R., Hughes, M., Waters, J., Cameron, J., Dodsworth, N., Tooth, D., Greenfield, A., & Sleep, D. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.05.009 · Cited by 40 · see citing works

FcRn binding properties of an abnormal truncated analbuminemic albumin variant

Andersen, J. T., Daba, M. B., & Sandlie, I. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.12.001 · Cited by 34 · see citing works

Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues

Andersen, J. T., Justesen, S. F. L., Fleckenstein, B. T., Michaelsen, T. E., Berntzen, G., Kenanova, V. E., Daba, M. B., Lauvrak, V., Buus, S., & Sandlie, I. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06551.x · Cited by 30 · see citing works

A homozygote for a serum albumin variant of the fast type

Vanzetti, G., Porta, F., Prencipe, L., Scherini, A., & Fraccaro, M. (1979) · Human Genetics · doi:10.1007/bf00278896 · Cited by 11 · see citing works

Untitled work

(1999) · doi:10.1002/(sici)1521-4141(199909)29:09

Hypoalbuminemia: Pathogenesis and Clinical Significance

Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1451 · Cited by 1,448 · see citing works

Albumin-based drug delivery: harnessing nature to cure disease

Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 690 · see citing works

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 466 · see citing works

Albumin and its application in drug delivery

Sleep, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 465 · see citing works

The Neonatal Fc Receptor (FcRn): A Misnomer?

Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 432 · see citing works

Biomacromolecules as carriers in drug delivery and tissue engineering

Zhang, Y., Sun, T., & Jiang, C. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.11.005 · Cited by 417 · see citing works

Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics

Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304 · see citing works

Developability Assessment During the Selection of Novel Therapeutic Antibodies

Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242 · see citing works

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy

Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 237 · see citing works

Synthetic fusion protein design and applications

Yu, K., Liu, C., Kim, B., & Lee, D. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.11.005 · Cited by 235 · see citing works

The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery

Bern, M., Sand, K. M. K., Nilsen, J., Sandlie, I., & Andersen, J. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.006 · Cited by 219 · see citing works

Half-life extended biotherapeutics

Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 193 · see citing works

Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment

Kintzing, J. R., Interrante, M. V. F., & Cochran, J. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.005 · Cited by 192 · see citing works

Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents

Bernardim, B., Cal, P. M. S. D., Matos, M. J., Oliveira, B. L., Martínez‐Sáez, N., Albuquerque, I. S., Perkins, E., Corzana, F., Burtoloso, A. C. B., Jiménez‐Osés, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13128 · Cited by 188 · see citing works

Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 186 · see citing works

A review of lipidation in the development of advanced protein and peptide therapeutics

Menacho‐Melgar, R., Decker, J. S., Hennigan, J. N., & Lynch, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.032 · Cited by 155 · see citing works

Derivatization with fatty acids in peptide and protein drug discovery

Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 137 · see citing works

Serum albumin: clinical significance of drug binding and development as drug delivery vehicle

Tayyab, S., & Feroz, S. R. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.08.003 · Cited by 119 · see citing works

Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications

Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 126 · see citing works

Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

Datta‐Mannan, A. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086488 · Cited by 110 · see citing works

Targeting FcRn to Generate Antibody-Based Therapeutics

Ward, E. S., & Ober, R. J. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.007 · Cited by 109 · see citing works

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment

AlQahtani, A. D., O’Connor, D., Dömling, A. S. S., & Goda, S. K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108750 · Cited by 106 · see citing works

Severe acute pancreatitis: capillary permeability model linking systemic inflammation to multiorgan failure

Komara, N., Paragomi, P., Greer, P. J., Wilson, A. S., Breze, C. R., Papachristou, G. I., & Whitcomb, D. C. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00285.2020 · Cited by 105 · see citing works

Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation

Freedy, A. M., Matos, M. J., Boutureira, O., Corzana, F., Guerreiro, A., Akkapeddi, P., Somovilla, V. J., Rodrigues, T., Nicholls, K., Xie, B., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b10702 · Cited by 104 · see citing works

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy

Tapia‐Galisteo, A., Compte, M., Álvarez‐Vallina, L., & Sanz, L. (2023) · Theranostics · doi:10.7150/thno.81494 · Cited by 105 · see citing works

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

Martins, J. P., Kennedy, P. J., Santos, H. A., Barrias, C. C., & Sarmento, B. F. C. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.007 · Cited by 102 · see citing works

Assessing developability early in the discovery process for novel biologics

Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 99 · see citing works

A human endothelial cell-based recycling assay for screening of FcRn targeted molecules

Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98 · see citing works

Albumin: An Emerging Opportunity in Drug Delivery

Rahimizadeh, P., Yang, S., & Lim, S. I. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0512-9 · Cited by 87 · see citing works

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer

Kelly, J. M., Amor‐Coarasa, A., Nikolopoulou, A., Wüstemann, T., Barelli, P. J., Kim, D., Williams, C. M., Zheng, X., Bi, C., Hu, B. X., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188722 · Cited by 84 · see citing works

Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin

Azevedo, C., Nilsen, J., Grevys, A., Nunes, R., Andersen, J. T., & Sarmento, B. F. C. C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.005 · Cited by 84 · see citing works

Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs

Roopenian, D. C., Low, B. E., Christianson, G. J., Proetzel, G., Sproule, T. J., & Wiles, M. V. (2015) · mAbs · doi:10.1080/19420862.2015.1008345 · Cited by 84 · see citing works

Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin

Schmidt, E. G. W., Hvam, M. L., Antunes, F., Cameron, J., Viuff, D., Andersen, B., Kristensen, N. N., & Howard, K. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.794248 · Cited by 85 · see citing works

Albumin-based drug designs for pharmacokinetic modulation

Pilati, D., & Howard, K. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801633 · Cited by 82 · see citing works

Dietary vs. pharmacological doses of zinc: A clinical review

Santos, H. O., Teixeira, F. J., & Schoenfeld, B. J. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.06.024 · Cited by 77 · see citing works

Human and mouse albumin bind their respective neonatal Fc receptors differently

Nilsen, J., Bern, M., Sand, K. M. K., Grevys, A., Dalhus, B., Sandlie, I., & Andersen, J. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32817-0 · Cited by 74 · see citing works

An intact C-terminal end of albumin is required for its long half-life in humans

Nilsen, J., Trabjerg, E., Grevys, A., Azevedo, C., Brennan, S. O., Stensland, M., Wilson, J. J., Sand, K. M. K., Bern, M., Dalhus, B., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0903-7 · Cited by 74 · see citing works

Protein Engineering Strategies for Improved Pharmacokinetics

Rondon, A., Mahri, S., Morales-Yánez, F., Dumoulin, M., & Rita Vanbever, A. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202101633 · Cited by 71 · see citing works

An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics

Bern, M., Nilsen, J., Ferrarese, M., Sand, K. M. K., Gjølberg, T. T., Lode, H. E., Davidson, R. J., Camire, R. M., Bækkevold, E. S., Foss, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0580 · Cited by 71 · see citing works

Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics

Famta, P., Shah, S., Jain, N., Srinivasarao, D. A., Murthy, A. N., Ahmed, T., Vambhurkar, G. B., Shahrukh, S., Singh, S. B., & Srivastava, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.034 · Cited by 68 · see citing works

TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors

Austin, R. J., Lemon, B. D., Aaron, W. H., Barath, M., Culp, P., DuBridge, R. B., Evnin, L. B., Jones, A. D., Panchal, A. P., Patnaik, P., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0061 · Cited by 65 · see citing works

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Mandrup, O. A., Ong, S. C., Lykkemark, S., Dinesen, A., Rudnik‐Jansen, I., Dagnæs-Hansen, N. F., Andersen, J. T., Álvarez‐Vallina, L., & Howard, K. A. (2021) · Communications Biology · doi:10.1038/s42003-021-01790-2 · Cited by 65 · see citing works

Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics

Jacobs, S. A., Gibbs, A. C., Conk, M., Yi, F., Maguire, D., Kane, C. M., & O’Neil, K. T. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv040 · Cited by 65 · see citing works

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 59 · see citing works

Human serum albumin binders: A piggyback ride for long-acting therapeutics.

Ullah, A., Shin, G., & Lim, S.-I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103738 · Cited by 57 · see citing works

Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)

Sand, K. M. K., Bern, M., Nilsen, J., Dalhus, B., Gunnarsen, K. S., Cameron, J., Grevys, A., Bunting, K. A., Sandlie, I., & Andersen, J. T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.587675 · Cited by 56 · see citing works

Protein Engineering: A New Frontier for Biological Therapeutics

Tobin, P. J., Richards, D., Callender, R., & Wilson, C. J. (2014) · Current Drug Metabolism · doi:10.2174/1389200216666141208151524 · Cited by 54 · see citing works

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo

Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 52 · see citing works

An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies

Marotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 50 · see citing works

Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets

Bradford, H. F., Haljasmägi, L., Menon, M., McDonnell, T. C. R., Särekannu, K., Vanker, M., Peterson, P., Wincup, C., Abida, R., González, R. F., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100894 · Cited by 50 · see citing works

Synthesis and Biological Evaluation of Homogeneous Thiol‐Linked NHC*‐Au‐Albumin and ‐Trastuzumab Bioconjugates

Matos, M. J., Labão‐Almeida, C., Sayers, C. T., Dada, O., Tacke, M., & Bernardes, G. J. L. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800872 · Cited by 48 · see citing works

Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs

Viuff, D., Antunes, F., Evans, L. R., Cameron, J., Dyrnesli, H., Ravn, B. T., Stougaard, M., Thiam, K., Andersen, B., Kjærulff, S., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.019 · Cited by 47 · see citing works

FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs

Larsen, M. T., Mandrup, O. A., Schelde, K. K., Luo, Y., Sørensen, K. D., Dagnæs‐Hansen, F., Cameron, J., Stougaard, M., Steiniche, T., & Howard, K. A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.004 · Cited by 44 · see citing works

Albumin-targeting of an oxaliplatin-releasing platinum( iv ) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo

Schueffl, H. H., Theiner, S., Hermann, G., Mayr, J., Fronik, P., Groza, D., Schoonhoven, S., Galvez, L., Sommerfeld, N. S., Schintlmeister, A., et al. (2021) · Chemical Science · doi:10.1039/d1sc03311e · Cited by 43 · see citing works

Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

Castro, L. S., Lobo, G. S., Pereira, P., Freire, M., Neves, M. C., & Pedro, A. (2021) · Vaccines · doi:10.3390/vaccines9040328 · Cited by 35 · see citing works

Recent Advancements and Strategies for Overcoming the Blood–Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma

Tincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 42 · see citing works

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

Davé, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E., Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1210747 · Cited by 42 · see citing works

Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins

Brandl, F., Merten, H., Zimmermann, M., Béhé, M. P., Zangemeister‐Wittke, U., & Plückthun, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.030 · Cited by 42 · see citing works

Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice

Richter, W. F., Christianson, G. J., Frances, N., Grimm, H. P., Proetzel, G., & Roopenian, D. C. (2018) · mAbs · doi:10.1080/19420862.2018.1458808 · Cited by 39 · see citing works

Albumin in patients with liver disease shows an altered conformation

Paar, M., Fengler, V. H., Rosenberg, D. J., Krebs, A., Stauber, R. E., Oettl, K., & Hammel, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02269-w · Cited by 38 · see citing works

Albumin is a reliable drug-delivering molecule: Highlighting points in cancer therapy

Asrorov, A. M., Mukhamedov, N., Kayumov, M., Yashinov, A., Wali, A., Yili, A., Mirzaakhmedov, S. Y., & Huang, Y. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100186 · Cited by 38 · see citing works

Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement

Larsen, M. T., Rawsthorne, H., Schelde, K. K., Dagnæs‐Hansen, F., Cameron, J., & Howard, K. A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.023 · Cited by 38 · see citing works

Antimicrobial Peptides from Amphibian Innate Immune System as Potent Antidiabetic Agents: A Literature Review and Bioinformatics Analysis

Soltaninejad, H., Zare‐Zardini, H., Ordooei, M., Ghelmani, Y., Ghadiri‐Anari, A., Mojahedi, S., & Hamidieh, A. A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/2894722 · Cited by 37 · see citing works

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

Mullin, M. J., McClory, J., Haynes, W. A., Grace, J., Robertson, N. J., & Heeke, G. V. (2024) · mAbs · doi:10.1080/19420862.2024.2341443 · Cited by 34 · see citing works

Development of a screen-printed carbon electrode based disposable enzyme sensor strip for the measurement of glycated albumin

Hatada, M., Tsugawa, W., Kamio, E., Loew, N., Klonoff, D. C., & Sode, K. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.005 · Cited by 33 · see citing works

A Platform for Site‐Specific DNA‐Antibody Bioconjugation by Using Benzoylacrylic‐Labelled Oligonucleotides

Konč, J., Brown, L., Whiten, D. R., Zuo, Y., Ravn, P., Klenerman, D., & Bernardes, G. J. L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109713 · Cited by 32 · see citing works

The bromocresol green assay, but not the modified bromocresol purple assay, overestimates the serum albumin concentration in nephrotic syndrome through reaction with α 2 -macroglobulin

Ueno, T., Hirayama, S., Sugihara, M., & Miida, T. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215574350 · Cited by 31 · see citing works

An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications

Kuhlmann, M., Hamming, J. B. R., Voldum, A., Τσακιρίδου, Γ., Larsen, M. T., Schmøkel, J. S., Sohn, E., Bieńk, K., Schaffert, D., Sørensen, E. S., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.004 · Cited by 32 · see citing works

Species Differences in Tryptophan Metabolism and Disposition

Badawy, A. A. ‐., & Guillemin, G. J. (2022) · International Journal of Tryptophan Research · doi:10.1177/11786469221122511 · Cited by 30 · see citing works

Albumin-based Drug Delivery Using Cysteine 34 Chemical Conjugates–Important Considerations and Requirements

Caspersen, M. B., Kuhlmann, M., Nicholls, K., Saxton, M. J., Andersen, B., Bunting, K. A., Cameron, J., & Howard, K. A. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0038 · Cited by 29 · see citing works

Animal models for evaluation of albumin-based therapeutics

Nilsen, J., Sandlie, I., Roopenian, D. C., & Andersen, J. T. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.007 · Cited by 27 · see citing works

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Felip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 25 · see citing works

Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia

Vodret, S., Bortolussi, G., Schreuder, A. B., Jašprová, J., Vı́tek, L., Verkade, H. J., & Muro, A. F. (2015) · Scientific Reports · doi:10.1038/srep16203 · Cited by 26 · see citing works

A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation

Schelde, K. K., Nicholls, K., Dagnæs‐Hansen, F., Bunting, K. A., Rawsthorne, H., Andersen, B., Finnis, C. J. A., Williamson, M., Cameron, J., & Howard, K. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005870 · Cited by 25 · see citing works

Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding

Schmøkel, J. S., Voldum, A., Τσακιρίδου, Γ., Kuhlmann, M., Cameron, J., Sørensen, E. S., Wengel, J., & Howard, K. A. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa6a9b · Cited by 26 · see citing works

Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus

Wang, J. W., Wu, W. H., Huang, T., Wong, M., Kwak, K., Ozato, K., Hung, C., & Roden, R. B. S. (2018) · Journal of Virology · doi:10.1128/jvi.00572-18 · Cited by 25 · see citing works

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models

Anthi, A., Kolderup, A., Vaage, E. B., Bern, M., Benjakul, S., Tjärnhage, E., Ruso-Julve, F., Jensen, K.-R., Lode, H. E., Vaysburd, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59353-6 · Cited by 23 · see citing works

Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

Iyengar, A. R. S., Gupta, S., Jawalekar, S. S., & Pande, A. H. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257063 · Cited by 24 · see citing works

Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry

Lee, J. J., Seraj, J., Yoshida, K., Mizuguchi, H., Strychor, S., Fiejdasz, J., Faulkner, T., Parise, R. A., Fawcett, P., Pollice, L., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2965-2 · Cited by 23 · see citing works

Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery

Azevedo, C., Pinto, S. F. T., Benjakul, S., Nilsen, J., Santos, H. A., Traverso, G., Andersen, J. T., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.016 · Cited by 24 · see citing works

Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants

Petersen, S. S., Kläning, E., Ebbesen, M. F., Andersen, B., Cameron, J., Sørensen, E. S., & Howard, K. A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00605 · Cited by 23 · see citing works

Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life

Bukrinski, J. T., Sønderby, P., Antunes, F., Andersen, B., Schmidt, E. G. W., Peters, G. H. J., & Harris, P. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00492 · Cited by 23 · see citing works

The neonatal Fc receptor in mucosal immune regulation

Aaen, K. H., Anthi, A. K., Sandlie, I., Nilsen, J., Mester, S., & Andersen, J. T. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13017 · Cited by 21 · see citing works

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity

Lombardi, S., Aaen, K. H., Nilsen, J., Ferrarese, M., Gjølberg, T. T., Bernardi, F., Pinotti, M., Andersen, J. T., & Branchini, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17559 · Cited by 21 · see citing works

Biology of Anti-TNF Agents in Immune-Mediated Inflammatory Diseases: Therapeutic Implications

Levy, R. A., Guzmán, R. A., Castañeda‐Hernández, G., Martinez-Vazquez, M. A., Damian, G. B., & Cara, C. (2016) · Immunotherapy · doi:10.2217/imt-2016-0067 · Cited by 21 · see citing works

Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil?

Popova, T. V., Khan, H., Chubarov, A. S., Lisitskiy, V. A., Antonova, N. M., Евгеньевич, А. А., Shevelev, O. B., Zavjalov, E. L., Silnikov, V. N., Ahmad, S., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.061 · Cited by 21 · see citing works

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review

Fieux, M., Quellec, S. L., Bartier, S., Coste, A., Louis, B., Giroudon, C., Nourredine, M., & Béquignon, É. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126475 · Cited by 20 · see citing works

Hemolysis Is Responsible for Elevation of Serum Iron Concentration After Regular Exercises in Judo Athletes

Nishiie-Yano, R., Hirayama, S., Tamura, M., Kanemochi, T., Ueno, T., Hirayama, A., Hori, A., Ai, T., Hirose, N., & Miida, T. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01981-3 · Cited by 21 · see citing works

Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans

Sepp, A., Bergström, M., & Davies, M. L. (2020) · mAbs · doi:10.1080/19420862.2020.1832861 · Cited by 18 · see citing works

Mechanism of how carbamylation reduces albumin binding to FcRn contributing to increased vascular clearance

Yadav, S. P. S., Sandoval, R. M., Zhao, J., Huang, Y., Wang, E., Kumar, S., Campos, S. B., Rhodes, G. J., Mechref, Y. S., Molitoris, B. A., et al. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00428.2020 · Cited by 20 · see citing works

A toolbox for microbore liquid chromatography tandem-high-resolution mass spectrometry analysis of albumin-adducts as novel biomarkers of organophosphorus pesticide poisoning

von der Wellen, J., Winterhalter, P., Siegert, M., Eyer, F., Thiermann, H., & John, H. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.04.025 · Cited by 21 · see citing works

Albumin: the next-generation Delivery Technology

Howard, K. A. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.124 · Cited by 20 · see citing works

Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds

Warnders, F.-J., Hooge, M. N. L., de Vries, E. G. E., & Kosterink, J. G. W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21498 · Cited by 18 · see citing works

Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin

Yang, B., Kim, J. C., Seong, J., Tae, G., & Kwon, I. (2018) · Biomaterials Science · doi:10.1039/c8bm00456k · Cited by 17 · see citing works

Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end

Nilsen, J., Aaen, K. H., Benjakul, S., Ruso‐Julve, F., Greiner, T. U., Bejan, D., Stensland, M., Singh, S. K., Schlothauer, T., Sandlie, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08249-8 · Cited by 18 · see citing works

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

Hangiu, O., Compte, M., Dinesen, A., Navarro, R., Tapia‐Galisteo, A., Mandrup, O. A., Erce-Llamazares, A., Lázaro‐Gorines, R., Nehme-Álvarez, D., Domínguez-Alonso, C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104958 · Cited by 17 · see citing works

A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics

Low, B. E., & Wiles, M. V. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_7 · Cited by 16 · see citing works

Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides

Amatya, R., Park, T., Hwang, S., Yang, J. W., Lee, Y.-J., Cheong, H., Moon, C., Kwak, H. D., Min, K. A., & Shin, M. C. (2020) · Toxins · doi:10.3390/toxins12050313 · Cited by 16 · see citing works

Human arginase 1, a Jack of all trades?

Anakha, J., Kawathe, P. S., Datta, S., Jawalekar, S. S., Banerjee, U. C., & Pande, A. H. (2022) · 3 Biotech · doi:10.1007/s13205-022-03326-9 · Cited by 16 · see citing works

Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Nicotiana benthamiana Plant With Potent Anti-SARS-CoV-2 Activity

Mamedov, T., Gürbüzaslan, İ., Yuksel, D., Ilgın, M., Mammadova, G., Özkul, A., & Hasanova, G. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.742875 · Cited by 15 · see citing works

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo

Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 52 · see citing works

Serum albumin and its interaction with the neonatal Fc receptor (FcRn) : characterization of the albumin/FcRn-binding mechanism

Färber-Schwarz, A. (2013) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-2165

The Influence of FcRn on Albumin-Fused and Targeted Drugs

Nilsen, J., Sand, K. M. K., Bern, M., Lei, P., Sandlie, I., & Andersen, J. T. (2016) · Springer eBooks · doi:10.1007/978-981-10-2116-9_10 · Cited by 1 · see citing works

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

Andersen, J. T., Pehrson, R., Максимилианович, Т. В., Daba, M. B., Abrahmsén, L., & Ekblad, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164848 · Cited by 177 · see citing works

Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end

Nilsen, J., Aaen, K. H., Benjakul, S., Ruso‐Julve, F., Greiner, T. U., Bejan, D., Stensland, M., Singh, S. K., Schlothauer, T., Sandlie, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08249-8 · Cited by 18 · see citing works